Should I stop Zepbound (tirzepatide) in a patient with mildly elevated aspartate aminotransferase (AST) at 35 U/L and alanine aminotransferase (ALT) at 60 U/L?

Do Not Stop Zepbound

You should continue Zepbound (tirzepatide) in this patient with mildly elevated liver enzymes (AST 35, ALT 60), as these values do not meet discontinuation thresholds and tirzepatide has demonstrated hepatoprotective effects in MASLD/MASH. 1

Clinical Context and Decision Framework

Your patient's liver enzymes are only minimally elevated:

• AST 35 U/L - essentially normal (typical ULN ~40 U/L)
• ALT 60 U/L - approximately 1.5× ULN (assuming ULN ~40 U/L)

These values fall far below any recognized discontinuation threshold for drug-induced liver injury (DILI).

FDA Stopping Rules for Normal Baseline Liver Enzymes

According to consensus guidelines for hepatic discontinuation, you should only consider stopping tirzepatide if the patient meets any one of these criteria 1:

1. ALT or AST ≥8× ULN (would be ≥320 U/L)
2. ALT or AST ≥5× ULN for more than 2 weeks (would be ≥200 U/L)
3. ALT or AST ≥3× ULN with total bilirubin ≥2× ULN or INR >1.5 (would be ALT ≥120 U/L plus elevated bilirubin/INR)
4. ALT or AST ≥3× ULN with hepatic symptoms (fatigue, nausea, vomiting, right upper quadrant pain, fever, or rash)

Your patient meets none of these criteria.

Tirzepatide's Hepatoprotective Profile

Importantly, tirzepatide actually improves liver health in patients with metabolic dysfunction-associated steatotic liver disease:

• In the SYNERGY-NASH trial, tirzepatide achieved 62% MASH resolution without worsening fibrosis at the 15 mg dose 2
• Tirzepatide significantly reduced ALT by 30.90% and AST by 20.71% in patients with type 2 diabetes 3
• It reduced hepatic steatosis by 34.90% as measured by MRI-PDFF 4

The mild ALT elevation you're observing is likely unrelated to tirzepatide and may represent underlying metabolic liver disease that tirzepatide could actually help improve.

What You Should Do Instead

Continue tirzepatide and implement the following monitoring strategy:

1. Recheck liver enzymes in 2-4 weeks to establish trend
2. Obtain baseline values if not already available - you need to know if this represents change from baseline
3. Check total bilirubin and INR to rule out more serious hepatocellular injury
4. Assess for hepatic symptoms - ask specifically about fatigue, nausea, RUQ pain, fever, rash
5. Evaluate alternative causes: alcohol use, other hepatotoxic medications, viral hepatitis, metabolic syndrome

Common Pitfall to Avoid

Do not automatically discontinue medications for mild transaminase elevations (<3× ULN) without symptoms or bilirubin elevation. This leads to premature discontinuation of potentially beneficial therapy 1. The guidelines explicitly state that "automatic discontinuation of a study drug upon finding a mild abnormality in liver enzymes is usually unnecessary" 1.

When to Actually Stop

Only discontinue tirzepatide if subsequent monitoring reveals:

• ALT rises to ≥8× ULN (≥320 U/L)
• ALT ≥3× ULN (≥120 U/L) plus total bilirubin ≥2× ULN or INR >1.5
• ALT ≥3× ULN (≥120 U/L) plus hepatic symptoms
• ALT ≥5× ULN (≥200 U/L) persisting for >2 weeks

Special Consideration

While rare case reports of tirzepatide-induced hepatotoxicity exist 5, 6, these are exceptional cases. The overwhelming evidence demonstrates tirzepatide's hepatoprotective effects 4, 2, 3, 7, making it unlikely that these minimal elevations represent drug-induced injury.